- Home
- ZURA vs AARD Comparison
ZURA vs AARD Comparison
Compare ZURA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | AARD |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 231.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZURA | AARD |
|---|---|---|
| Price | $4.31 | $14.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $11.38 | ★ $30.63 |
| AVG Volume (30 Days) | ★ 369.0K | 279.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $4.88 |
| 52 Week High | $4.68 | $19.58 |
Technical Indicators
Market Signals| Indicator | ZURA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 62.49 |
| Support Level | $3.88 | $12.90 |
| Resistance Level | $4.45 | $16.00 |
| Average True Range (ATR) | 0.25 | 1.29 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 89.36 | 74.29 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.